calo

Caloxin 2A1 acetate is an inhibitor of extracellular plasma membrane Ca2+-ATPase (PMCA) peptide. Caloxin 2A1 acetate inhibits Ca2+-dependent formation of the 140-kDa acid-stable acylphosphate.

Caloxin 2A1 TFA is a peptide inhibitor specifically targeting the extracellular plasma membrane Ca2+-ATPase (PMCA), without influencing the basal activities of Mg2+-ATPase or Na+-K+-ATPase[1].

Caloxin 1B1, a bioactive peptide, exhibits selective inhibition of PMCA extracellularly by binding preferentially to the extracellular domain 1 of PMCA4 over PMCA1. Identified through a screening process for its high-affinity interaction with PMCA, Caloxin 1B1 is capable of direct application to cells and tissues, facilitating research into its impact on smooth muscle and endothelium.

Caloxin 3A1, a biologically active peptide, is a member of the caloxins, which are inhibitors of the extracellular plasma membrane (PM) Ca2+ pumps. Specifically, it inhibits plasma membrane calcium pumps (PMCAs) without affecting the sarcoplasmic reticulum Ca2+ pump, nor does it inhibit the formation of the acylphosphate intermediate from ATP.

Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is a luteinizing hormone-releasing hormone (LHRH) analogue possessing antineoplastic properties, characterized by the peptide sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG. It demonstrates effectiveness in inhibiting breast, ovarian, and prostate cancer xenografts in mouse models [1] [2].

Caloxin 2A1 is an inhibitor peptide of the plasma membrane Ca 2+-ATPase (PMCA) responsible for extracellular signaling. Importantly, Caloxin 2A1 has no impact on the basal Mg 2+-ATPase or Na+-K+-ATPase activities.